# Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis

> **NCT07228325** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Nasus Pharma** · enrollment: 50 (estimated)

## Conditions studied

- Anaphylaxis
- Allergy

## Interventions

- **DRUG:** FMXIN002 single dose
- **DRUG:** Epinephrine autoinjector single dose
- **DRUG:** FMXIN002 single dose + NAC
- **DRUG:** Epinephrine autoinjector double dose
- **DRUG:** FMXIN002 double dose
- **DRUG:** FMXIN002 double dose + NAC

## Key facts

- **NCT ID:** NCT07228325
- **Lead sponsor:** Nasus Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-03
- **Primary completion:** 2026-03
- **Final completion:** 2026-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228325, "Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07228325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*